Myasthenia Gravis
Background
Kamagra online
There are two peaks of incidence in patients with acquired myasthenia gravis. One peak occurs in early adulthood (25-35). In this group, women outnumber men 2:1. In the older peak (55-70) the ratio of men to women is 1:1. Patients with myasthenia gravis have a high occurrence of co-existing autoimmune disease. For example, antibody mediated thyroid disorders occur in 20% of myasthenic patients. Rheumatoid arthritis, lupus, pernicious anemia, sarcoid, Sjogren’s, polymyositis, ulcerative colitis, and pemphigus have been described in patients with myasthenia. Most authors estimate that 3-4% of patient with myasthenia have one of these diseases. Thymic hyperplasia is found in 75% of patients and transcervical thymectomy is the treatment of choice, providing 85% of patients complete remission off medication within 8 years. However, the recommendation for thymectomy for older patients remains controversial. Thymoma is a definite indication for thymectomy and occurs in 10% of patients with myasthenia gravis. Rarely, patients may present with thymoma only to have myasthenia recur after diagnosis or even after thymectomy.
Cheap Zithromax
Pathophysiology
Myasthenia gravis is an autoimmune disease caused by an antibody directed against the acetylcholine receptor (AChR). The source of the antibody and its relation to thymic abnormalities is beyond the scope of the discussion; however, there is substantial evidence relating the two. The antibodies are usually polyclonal but most bind to epitopes in a small extracellular portion of the alpha subunit of the receptor. This site is designated as the main immunogenic region (MIR). It is not the site that binds acetylcholine. Antibodies that bind to the MIR are able to fix complement, passively transfer MG to animals, and modulate function of the AChR when applied to experimental preparations. Clinical assays of blocking antibodies reveal their presence in 52% of patients but rarely (1%) as the only type of antibody detected. Modulating antibodies are present in 90% of sera. Striational antibodies are present in 84% of patients with thymoma. However, they may be found in elderly myasthenic patients with thymic atrophy. Another antibody to titin is also helpful in detecting thymoma.
Cialis super active – erectile dysfunction treatment.
There are known associations with different types of myasthenia with specific HLA haplotypes suggesting that the susceptibility to develop MG is genetically controlled. In patients under 40, there is an increased prevalence of HLA A 1, B8, and DRw3 and acetylcholine receptor antibodies are usually present. In patients over 40, there is and increase in HLA A3, B7 and DRw2. Acetylcholine receptor titers are usually low. Thymomas do not occur in these patients. Tumor necrosis factor alpha is a cytokine with prominent effects on the neuroimmune system and is frequently elevated in myasthenic patients. Recent studies have shown that the gene for TNF alpha is just as closely associated with myasthenic patients below 40 with thymic hyperplasia as B8 and DRw3.
Clinical Manifestations
Ocular involvement occurs in more than 90% of all patients in the form of ptosis and impaired ocular movements. Ophthalmoplegia is possible. In 60% of myasthenic patients, nasal speech, slurred speech, and difficulty swallowing occurs. If untreated or in crisis, respiratory impairment or failure occurs. In 30-40% of patients, limb weakness is experienced. The cardinal manifestation of the clinical manifestations of myasthenia is that all symptoms worsen with exertion (and therefore are best in the morning) and are reversible with edrophonium. The characteristic electrodiagnostic manifestations include normal nerve conduction studies, normal evoked response amplitudes, and decrement on repetitive stimulation. Single fiber EMG is abnormal. Needle EMG shows no spontaneous activity and motor units that vary in amplitude during repetitive firing.
Canadian viagra
Therapy is directed at reducing the level of circulating antibody. The most rapid and effective therapy is plasmapheresis. Target therapy is one blood volume over 5 days. Recent studies suggest a specific immunoabsorbent (Medisorba) column provides more selective therapy. Intravenous immunoglobulin has been recommended as a B level treatment for myasthenia gravis (ie, a treatment of last resort). Chronic therapy usually consists of steroids (prednisone, alternate day therapy if possible), azathioprine, and cyclophosphamide. Recent observations have shown that nasal inhalation of recombinant fragments of the immunogenic extracellular portion of the alpha subunit have produced tolerance in animals with experimental myasthenia gravis and have protected animals from acquiring EAMG suggesting a possible future therapy for humans.
Myasthenic crisis is a medical emergency and defined as acute respiratory deterioration in a patient with known myasthenic gravis or rarely, as the presenting manifestation. It develops in 15-20% of all myasthenic patients. The most common interval between crisis and first symptom is 8 months. The causes of myasthenic crisis include infection, reduction in medication, initiation of steroid therapy, and uncertain. The mortality rate is approximately 4% and is due to adult respiratory distress syndrome, multiple organ failure, cardiac failure, or resistant infection.
Recent Comments